Pfizer (PFE) Following FDA Vaccine Approval Has Fair Value Back In Focus

Why the new COVID-19 vaccine approval matters for Pfizer stock

Pfizer (PFE) and BioNTech just received FDA approval for their 2026 to 2027 COMIRNATY XFG COVID-19 vaccine for certain higher risk groups, a decision that opens the door to fresh U.S. vaccine shipments.

Pfizer’s share price has picked up recently, with a 30 day share price return of 14.15% and a 90 day share price return of 12.67%. The 1 year total shareholder return of 22.31% comes after several years of weaker total returns. Recent catalysts include this latest COVID 19 vaccine approval, a confidential Depo Provera settlement that reduced legal uncertainty, stronger Q2 results, and ongoing progress in the oncology pipeline. These factors help explain why momentum now looks stronger than earlier in the multi year period.

Capitalize on Pfizer’s renewed momentum by scanning a curated 50 high quality undervalued stocks that share solid fundamentals and could be poised for their own catalyst driven re rating.

After a sharp 30 day move and fresh vaccine news, Pfizer now sits close to analyst targets while still trading at a large estimated intrinsic discount. Is it worth stepping in here or waiting for a cleaner entry based on valuation?

Most Popular Narrative: 2.2% Undervalued

Pfizer's most followed narrative puts fair value at about $29.19 per share, only slightly above the last close at $28.55, yet it builds that view on some punchy long term assumptions.

Robust expansion of Pfizer's late-stage pipeline, especially in oncology and rare diseases, with multiple high-potential launches and label expansions (e.g., Elrexfio in multiple myeloma, SV in non-small cell lung cancer, advanced ADC portfolio, and pipeline vaccines), stands to drive sustained long-term revenue and earnings growth by addressing rising global demand for innovative therapies as the population ages.

Read the complete narrative.

Want to know how that kind of pipeline story results in only a small valuation gap today? The narrative leans heavily on margin expansion and a richer profit multiple to bridge the distance between shrinking headline revenue assumptions and higher projected earnings power.

Result: Fair Value of $29.19 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Pfizer narrative still faces real pressure from a projected revenue decline, as well as a patent cliff that could hit key oncology and specialty products.

Find out about the key risks to this Pfizer narrative.

Another View on Pfizer: What P/E Is Saying

While the SWS DCF model points to a large gap between Pfizer's share price and estimated cash flow value, the earnings multiple sends a cooler message. Pfizer trades on a P/E of 37.5x, which is higher than the US pharmaceuticals industry at 16.6x and above its own fair ratio of 28.3x. For investors, that means less margin for error if the pipeline or earnings path disappoints.

This raises a simple question: Should you place more weight on the cash flow story or on the richer earnings multiple when weighing Pfizer today?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mixed signals around Pfizer's momentum and valuation, it helps to see the full picture for yourself and move quickly while sentiment is shifting. Balance the concerns and potential upside by reviewing the 2 key rewards and 4 important warning signs.

Looking for more investment ideas beyond Pfizer?

If you stop at Pfizer, you risk missing other opportunities that could fit your goals even better. Take a few minutes to scan fresh ideas with the Simply Wall Street Screener and see what else deserves a spot on your radar.

• Target income-focused opportunities by reviewing stocks in the 12 dividend fortresses that offer higher yields while still showing resilient fundamentals.
• Hunt for mispriced potential by scanning the 19 high quality undiscovered gems that pair strong business quality with limited market attention.
• Prioritize capital preservation by checking companies highlighted in the 74 resilient stocks with low risk scores that combine sturdier balance sheets with lower overall risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com